Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

A Cautious Guide To The Interpretation Of Clinical Trials From NEJM

Executive Summary

Determining the success or failure of a randomized trial requires looking beyond the p-value for the primary endpoint, review articles in The New England Journal of Medicine urge.


Related Content

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout
When Oncology NDAs Fail, Clinical Benefit Is Often In Question
FDA Changed Course On Zontivity Because Of Skepticism Of Subgroups At High Levels
Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst